ÂÜÀòÂÒÂ×

Thierry Kimmerlin is an experienced professional in drug discovery chemistry with a career spanning from 2005 to the present. Currently serving as Associate Director at Idorsia Pharmaceuticals Ltd since June 2017, Thierry specializes in the hit-to-lead phase of drug discovery. Previously, Thierry held multiple positions at Actelion, starting in 2008, where responsibilities included leading a high-throughput medicinal chemistry team and overseeing the design and synthesis of compound libraries aimed at enhancing hit compounds and addressing early ADME issues. Prior to this, Thierry was the Lab Head of Chemistry at Novartis Institutes for BioMedical Research from January 2005 to June 2008. Thierry earned a PhD in Chemistry from ETH Zürich in 2005 and a DEA in Chemistry from Université Louis Pasteur (Strasbourg I) in 2000.